Sana Biotechnology (SANA) Net Cash Flow (2020 - 2026)

Sana Biotechnology has reported Net Cash Flow for 7 years, with the latest figure at $11.9 million in Q1 2026.

• Quarterly Net Cash Flow rose 138.39% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.3 million (up 84.69% YoY) and the FY2025 annual result came in at -$55.3 million, down 829.81% from the prior year.
• Net Cash Flow climbed to $11.9 million in Q1 2026 per SANA's latest filing, from -$31.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $43.5 million in Q1 2024 and troughed at -$64.5 million in Q1 2022.
• A 5-year average of -$10.2 million and a median of -$12.0 million in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 502.99% in 2025, down 5624.04% in 2025.
• Over 5 years, Net Cash Flow stood at $13.4 million in 2022, then sank by 360.25% to -$34.9 million in 2023, then soared by 101.63% to $570000.0 in 2024, then plunged by 5624.04% to -$31.5 million in 2025, then surged by 137.89% to $11.9 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $11.9 million, -$31.5 million, and $32.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.